Screener
Krystal Biotech, Inc. KRYS Operating Lease ROU Assets
Operating Lease ROU Assets at other companies
Other financials
Where this comes from
Reported directly by Krystal Biotech, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent.
The source filing: Krystal Biotech, Inc.’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 7:06 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001711279-26-000043
As of March 31, 2026 and December 31, 2025, the Company’s weighted-average remaining lease term for operating leases was 10.0 years and 10.1 years, respectively, and the Company’s weighted-average discount rate for operating leases was 9.7% as of March 31, 2026 and December 31, 2025.
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Krystal Biotech, Inc.'s operating lease ROU assets?
- Krystal Biotech, Inc. (KRYS) reported operating lease ROU assets of 9.7% in Q1 2026.
- How has Krystal Biotech, Inc.'s operating lease ROU assets changed year-over-year?
- Krystal Biotech, Inc.'s operating lease ROU assets increased by 1.0% year-over-year, from 9.6% to 9.7%.
- What is the long-term trend for Krystal Biotech, Inc.'s operating lease ROU assets?
- Over 5 years (2020 to 2025), Krystal Biotech, Inc.'s operating lease ROU assets has grown at a -96.9% compound annual growth rate (CAGR), from 329,800,000% to 9.7%.
- What does operating lease ROU assets mean?
- Right-of-use assets representing the lessee's right to use leased property over the lease term under ASC 842 operating lease classification.
Ask your AI about Krystal Biotech, Inc.'s operating lease rou assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude